A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 13 Apr 2011 ClinicalTrials.gov record identified and integrated.